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ABSTRACT
Objective: To characterize temporal trends in subarachnoid hemorrhage (SAH) incidence and out-
comes over 5 time periods in a large population-based stroke study in the United States.
Methods: All SAHs among residents of the Greater Cincinnati/Northern Kentucky region at
least 20 years of age were identified and verified via study physician review in 5 distinct
year-long study periods between 1988 and 2010. We abstracted demographics, care pat-
terns, and outcomes, and we compared incidence and case-fatality rates across the study
periods.
Results: The incidence of SAH in the 5 study periods (age-, race-, and sex-adjusted to the 2000
US population) was 8.8 (95% confidence interval 6.8–10.7), 9.2 (7.2–11.2), 10.0 (8.0–12.0),
9.0 (7.1–10.9), and 7.7 (6.0–9.4) per 100,000, respectively; the trend in incidence rates from
1988 to 2010 was not statistically significant (p 5 0.22). Advanced neurovascular imaging,
endovascular coiling, and neurologic intensive care unit availability increased significantly over
time. All-cause 5-day (32%–18%, p5 0.01; for trend), 30-day (46%–25%, p5 0.001), and 90-
day (49%–29%, p 5 0.001) case-fatality rates declined from 1988 to 2010. When we included
only proven or highly likely aneurysmal SAH, the declines in case-fatality were no longer statis-
tically significant.
Conclusions: Although the incidence of SAH remained stable in this population-based region, 5-
day, 30-day, and 90-day case-fatality rates declined significantly. Advances in surgical and med-
ical management, along with systems-based changes such as the emergence of neurocritical care
units, are potential explanations for the reduced case-fatality. Neurology® 2016;87:2192–2197
GLOSSARY
aSAH 5 aneurysmal subarachnoid hemorrhage; CI 5 confidence interval; GCNK 5 Greater Cincinnati/Northern Kentucky;
GCS 5 Glasgow Coma Scale; ICD-9 5 International Classification of Diseases–9; ICH 5 intracerebral hemorrhage; ICU 5
intensive care unit; mRS 5 modified Rankin Scale; SAH 5 subarachnoid hemorrhage.
There have been several advances in recent years in the diagnosis and care of subarachnoid hem-
orrhage (SAH) patients, including medical advances, new systems of standardized care in neuro-
critical care units, and new surgical and endovascular techniques for aneurysmal SAH.1,2 Recent
studies have reported SAH outcomes over time within the same population,3,4 but to our
knowledge there have been no such recent studies in the United States. We therefore sought
to examine temporal trends in nontraumatic SAH incidence, care patterns, and outcomes in
a large US region using population-based data.
METHODS Standard protocol approvals, registrations, and patient consents. This study was approved by the institutional
review boards of all participating hospitals in all 5 time periods.
We identified incident nontraumatic SAHs among residents of the Greater Cincinnati/Northern Kentucky (GCNK) region who
were 20 years old or older in 5 distinct 1-year study periods: calendar year 1988, July 1993 to June 1994, and calendar years 1999,
2005, and 2010. The GCNK region is composed of 2 southwestern Ohio counties and 3 northern Kentucky counties, all bordering
the Ohio River. The biracial population is approximately 1.3 million and is largely representative of the United States in terms of age,
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proportion of African Americans, and socioeconomic status.5 On-
ly residents of the 5 GCNK counties were included in our study.
Previous work has demonstrated that patients who live in this 5-
county region seek stroke care at the hospitals in the region.5
The 1988 cohort. The detailed methodology of the 1988 study
has been reported previously.6 Briefly, the records of all patients
who possibly had SAH or intracerebral hemorrhage (ICH) were
reviewed from local hospitals and the county coroner offices.
ICD-9 codes for SAH (430), ICH (431 and 432.9), cerebral
aneurysm (437.3), arteriovenous malformation (747.81), and
cerebrovascular accident (436) were used to retrieve records. A
trained nurse under the close supervision of a vascular neurologist
reviewed the records. The neurologist reviewed the clinical
data and all available CT and MRI. Patients with both SAH
and ICH were not included if a parenchymal source of
bleeding was more likely.
The 1993–1994, 1999, 2005, and 2010 cohorts. The
methods of the GCNK studies for 1993–1994, 1999, and
2005 have also been described previously.5,7,8 Ascertainment
methods remained consistent over time and those for 2010 were
as described for the other years. Briefly, study nurses screened the
hospital charts of all patients with primary or secondary stroke-
related ICD-9 codes of 430–436. Additional screening included
monitoring of emergency departments, public health clinics,
outpatient clinics, and family practice centers. The records of
the 5 county coroner’s offices were also monitored for stroke
deaths. A study physician then reviewed every potential case to
determine case status.
Aneurysmal SAH (aSAH) cohort. Because ruptured aneur-
ysms are the leading cause of nontraumatic SAH, we also per-
formed a subanalysis in which we identified proven or highly
likely aSAH. We reviewed all cases with unknown etiology and
categorized them as likely aneurysmal if the SAH was reported
as “massive” or if the patient suddenly died shortly after SAH.
Incidence rates. We calculated incidence rates for each time
period and age-, race-, and sex-adjusted to the 2000 US
population. The denominators for incidence rate calculations
were based on population estimates from the US Census
Bureau (census.gov) for the 5 study counties, with interpolation
between census years accounting for migration, death, and birth.
We estimated confidence intervals (CIs) assuming a Poisson
distribution.
Demographics, care patterns, and outcomes. We evaluated
basic patient demographics, vascular risk factors, care characteris-
tics, and functional status at baseline. Because SAH severity scales
were not uniformly abstracted in the form of Hunt and Hess or
World Federation of Neurological Surgeons scales, the admission
Glasgow Coma Scale (GCS) served as a proxy for baseline SAH
severity. Major clinical outcomes included modified Rankin Scale
(mRS) scores at hospital discharge and all-cause case-fatality at 5,
30, and 90 days after initial SAH. Because treatment location was
not uniformly abstracted at the patient level, we report the
proportion of patients treated at hospitals with neurologic
intensive care unit (ICU) availability in each time period.
Statistical analysis. Data were managed and analyzed using
SAS version 9.3 (SAS Institute, Cary, NC). Univariate compari-
sons were performed using analysis of variance, Kruskal-Wallis, or
x2 tests as appropriate. Regression modeling was utilized for
examining trends over time, linear or logistic dependent upon
the outcome of interest. SAS PROC GENMOD with the
appropriate distribution and link function was used. The offset
option was invoked for testing the trend in incidence rates over
time. A Tukey-Kramer correction was used as appropriate to
adjust for multiple comparisons. Some analyses were performed
excluding 1998 due to unavailable data.
RESULTS We identified 433 SAHs among residents
of the GCNK region: 79 SAHs in 1988, 84 from July
1993 to June 1994, 95 in 1999, 91 in 2005, and 84
in 2010. Across the 5 time periods, 305 patients
(70.4%) were women, 106 (24.5%) were black,
407 (94.0%) were diagnosed in an emergency room
or hospital setting, and 26 (6.0%) were diagnosed
on autopsy alone. In 1988, 10 SAHs were found at
autopsy (12.7% of total), compared with 6 (7.1%)
in 1993–1994, 4 (4.2%) in 1999, 3 (3.3%) in
2005, and 3 (3.6%) in 2010 (p value for trend is
0.01). Of the 433 SAHs, 319 (73.7%) were proven
or highly likely aSAH. Although the distribution of
aSAH cases varied over time—45 (57.0%) were iden-
tified as aSAH in 1988, 67 (79.8%) in 1993–1994,
79 (83.2%) in 1999, 65 (71.4%) in 2005, and 63
(75.0%) in 2010 (p 5 0.001)—there was no distinct
temporal trend (p 5 0.11).
Incidence rates. The incidence of SAH in the 5 study
periods (age-, race-, and sex-adjusted to the 2000 US
population) was 8.8 (95% CI 6.8–10.7), 9.2 (7.2–
11.2), 10.0 (8.0–12.0), 9.0 (7.1–10.9), and 7.7 (6.0–
9.4) per 100,000, respectively; the trend in incidence
rates from 1988 to 2010 was not statistically
significant (p 5 0.22).
Demographics and care patterns. Demographics and
risk factors across time periods are shown in table 1.
Age, sex, race, and presenting GCS were not different
among the time periods. There were no significant
trends in baseline characteristics except for an increase
in current smoking and a decrease in the proportion
of baseline mRS scores of 0–1. Diagnostic imaging
and treatment trends over time are shown in table 2.
The use of both CT and MRI increased significantly
from 1993–1994 to 2010, as did CT angiography
and magnetic resonance angiography. The proportion
of patients who underwent coiling increased to 13%
in 2010 from 0% in 1993–1994. There was a trend
toward reduction of time to intervention as well. Care
at a hospital with a neurologic ICU available also
increased substantially over the study periods.
Outcomes. Short-term SAH outcomes over time are
shown in table 3 and in the figure. Median discharge
mRS scores at hospital discharge declined signifi-
cantly from 5 to 3. All-cause 5-day, 30-day, and
90-day case-fatality rates declined significantly from
1988 to 2010, even when all autopsy-alone cases were
excluded. The largest decreases in case-fatality rates
occurred between 1988 and 1999. The majority of
deaths occurred within 5 days post onset in all time
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periods. We performed an additional analysis with
those patients with proven or highly likely aSAH
with the results shown in table 4. Though the
trends were generally similar to those in table 3, the
results were no longer statistically significant. Because
so many SAHs from 1988 had an unknown etiology,
we performed an additional analysis excluding 1988
and again found that improved case-fatality rates did
not reach statistical significance.
DISCUSSION In this large population-based study
spanning multiple study periods, we found that
although SAH incidence rates remained unchanged,
all-cause case-fatality rates declined significantly. We
also found a significant shift in SAH care across
these time periods, which included changes in
autopsy rates, imaging, interventions, and systemic
changes such as neurologic ICU utilization.
Recent systematic reviews have evaluated the inci-
dence of SAH in several countries.9,10 In general,
these studies have found that the incidence of SAH
has remained relatively stable over the last several
decades. The incidence is generally higher in Japan
and Scandinavia (;20 per 100,000) and lower in
South and Central America (;5 per 100,000). The
only study that has evaluated temporal trends in inci-
dence in the United States of which we are aware is
the Rochester, Minnesota, study, in which investiga-
tors identified 185 SAHs in Olmsted County from
1955 to 1989. The incidence rate ranged from 7.5 to
12.9 per 100,000, and the changes across 5-year time
periods were not statistically significant.11 The cur-
rent study includes more than twice the number of
SAHs, as well as a more recent cohort with a minority
population as well.
Systematic reviews have also found reductions in
SAH case-fatality in multiple population-based stud-
ies in several countries,4,12 though few studies have
reported case-fatality rates across multiple time peri-
ods, and none in the United States.4 (The Rochester
study reported 30-day and 1-year survival stratified by
sex and 5-year period, but the overall case-fatality per
Table 2 Use of imaging and treatments in subarachnoid hemorrhage (SAH) patients by time period
1988 (n 5 79) 1993–1994 (n 5 84) 1999 (n 5 95) 2005 (n 5 91) 2010 (n 5 84) p Value for trend
Imaging (MRI/CT) 69 (87) 73 (87)a 91 (96) 89 (98) 82 (98) 0.002
MRI NA 8 (10) 7 (7) 28 (31) 18 (21) 0.002
CT 69 (87) 73 (87) 91 (96) 88 (97) 82 (98) 0.001
MRA NA 3 (3.6) 5 (5.3) 18 (19.8) 7 (8.3) 0.02
CTA NA NA NA 22 (24.2) 51 (60.7) ,0.0001
Cerebral angio 44 (56) 40 (48) 75 (79) 63 (69) 32 (38) 0.52
Clip/coil 30 (38) 30 (36) 58 (61) 47 (52) 46 (55) 0.001
Clip 30 (38) 30 (36) 57 (60) 33 (36) 36 (43)b 0.60
Coil 0 (0) 0 (0) 1 (1) 14 (15) 11 (13)b 0.004
Time to clip/coil, h 234 (79, 409) [4, 7,363] 65 (23, 141) [3, 363] 29 (15, 88) [6, 384] 21 (12, 38) [4, 315] 23 (18, 39) [3, 302] 0.052
Neurologic ICU available 22 (28) 30 (36) 59 (62) 66 (73) 71 (85) ,0.0001
Abbreviations: CTA 5 CT angiography; ICU 5 intensive care unit; MRA 5 magnetic resonance angiography; NA 5 not available.
Data presented as n (%) or median (25th, 75th percentile) [minimum, maximum].
a Some data missing.
bOne patient in 2010 underwent clipping and coiling.
Table 1 Baseline characteristics of subarachnoid hemorrhage (SAH) patients by time period
1988 (n 5 79) 1993–1994 (n 5 84) 1999 (n 5 95) 2005 (n 5 91) 2010 (n 5 84) p Value for trend
Age, y, median (IQR) 55 (42–67) 62 (46–73) 51 (42–65) 56 (44–70) 56 (48–66) 0.94
Female, n (%) 50 (63) 58 (69) 71 (75) 67 (74) 59 (70) 0.25
Black, n (%) 18 (23) 17 (20) 21 (22) 27 (30) 23 (27) 0.19
GCS, median (IQR) NA 14 (4.5–15) (n 5 64) 15 (9–15) (n 5 88) 15 (7–15) (n 5 79) 15 (9.5–15) (n 5 76) 0.15
Hypertension, n (%) 42 (53) 38 (45) 46 (48) 52 (57) 47 (56) 0.27
Current smoking, n (%) 24 (30) 25 (30) 42 (44) 38 (42) 38 (45) 0.01
Baseline mRS (0–1), n (%) NA 64/71 (90) 74/80 (92) 69/89 (78) 62/82 (76) 0.002
Abbreviations: GCS 5 Glasgow Coma Scale; IQR 5 interquartile range; mRS 5 modified Rankin Scale; NA 5 not available.
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time period was not reported.) Most of these studies
also began surveillance in the 1980s and generally
found declines in early case-fatality rates that mirror
the declines we report, though most did not find
these declines to be statistically significant.
Several changes in SAH care over the last 25 years
are mirrored in our data. The numbers of SAHs diag-
nosed by autopsy declined as autopsy rates have
declined nationwide.13 Noninvasive angiography is
replacing conventional angiography for SAH diagno-
sis.14 Surgical intervention was commonly delayed
10–12 days after SAH until the 1980s, but is now
often performed as early as feasible to reduce rebleed-
ing risk.2 Less-invasive endovascular coiling is more
common.15,16 Specialized stroke units and neurologic
ICUs, with an emphasis on multidisciplinary collab-
oration, protocolization, and continuous quality
improvement, are more prevalent17 and associated
with improved patient outcomes.18 At the systems
of care level, the development of primary stroke cen-
ters19 and comprehensive stroke centers20 has also
driven quality improvement in stroke care.
Though aneurysmal rupture is the most frequent,
other etiologies of nontraumatic SAH include peri-
mesencephalic nonaneurysmal SAH, arteriovenous
malformations, dissection, amyloid angiopathy, and
reversible cerebral vasoconstriction syndrome. Using
a conservative threshold for aSAH, we found that at
least 75% of SAHs were highly likely aneurysmal in
etiology in our population, which is in line with pre-
vious reports.21 The trends in case-fatality decline in
the aSAH subanalysis appeared generally similar to
that of the overall cohort, though the statistical sig-
nificance disappeared likely due to the smaller sample
size. Another potential explanation is that improved
imaging identified smaller nonaneurysmal SAHs,
which typically are not life-threatening. As noted
above, though, we did not identify a trend toward
more nonaneurysmal SAHs in the later time periods.
The GCNK Stroke Study is the largest
population-based stroke study in the United States,
with the same population evaluated over multiple
time periods and with many of the same study per-
sonnel, using a stable methodology. However, there
are several limitations to this study. First, in this
observational study the data are retrospective and
descriptive in nature; this study cannot answer why
case-fatality rates are declining. There are several data
points missing from 1988, including severity scores
and baseline functional status. There was no consis-
tent formal grading of SAH severity documented in
the medical records across time periods, though
Table 3 Functional outcomes and case-fatality by time period
1988 (n 5 79) 1993–1994 (n 5 84) 1999 (n 5 95) 2005 (n 5 91) 2010 (n 5 84) p Value for trend
All SAHs
Discharge mRS, median (IQR) NA 5 (4–6) (n 5 77) 4 (2–6) (n 5 89) 4 (2–5) (n 5 89) 3 (2–5) (n 5 82) 0.02a
5-day case-fatality 25 (32) [21–42] 22 (26) [17–36] 20 (21) [13–29] 16 (18) [10–25] 15 (18) [10–26] 0.01
30-day case-fatality 36 (46) [35–57] 34 (40) [30–51] 31 (33) [23–42] 25 (27) [18–37] 21 (25) [16–34] 0.001
90-day case-fatality 39 (49) [38–60] 36 (43) [32–53] 32 (34) [24–43] 28 (31) [21–40] 24 (29) [19–38] 0.001
Coroner’s cases 10 (13) 6 (7) 4 (4) 3 (3) 3 (4) 0.008
1988 (n 5 69) 1993–1994 (n 5 78) 1999 (n 5 91) 2005 (n 5 88) 2010 (n 5 81) p Value for trend
Hospital-only (coroner’s cases
excluded)
Discharge mRS (median, IQR) NA 4 (3.5–6) (n 5 77) 4 (1.5–6) (n 5 88) 4 (2–5) (n 5 88) 3 (2–5) (n 5 81) 0.01a
5-day case-fatality 15 (22) [12–31] 16 (21) [12–29] 16 (18) [10–25] 13 (15) [7–22] 12 (15) [7–23] 0.15
30-day case-fatality 26 (38) [26–49] 28 (36) [25–47] 27 (30) [20–39] 22 (25) [16–34] 18 (22) [13–31] 0.01
90-day case-fatality 29 (42) [30–54] 30 (38) [28–49] 28 (31) [21–40] 25 (28) [19–38] 21 (26) [16–35] 0.01
Abbreviations: CI 5 confidence interval; IQR 5 interquartile range; mRS 5 modified Rankin Scale; NA 5 not available; SAH 5 subarachnoid hemorrhage.
Values are n (%) [95% CI] unless noted otherwise.
a Adjusting for baseline mRS.
Figure Short-term subarachnoid hemorrhage (SAH) outcomes over time
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presenting GCS was used as a surrogate. Emerging
evidence suggests that psychological and cognitive
burden of disease in SAH is significant,22 but we
cannot comment on those outcome domains in the
current study. We also did not collect data on either
aggressiveness of care or withdrawal of care across all
time periods, so we cannot comment on whether
case-fatality rates may be declining because fewer
families or physicians are withdrawing care. Case-
fatality rates may appear lower because cases formerly
identified on autopsy are not now identified. We also
cannot comment on overall autopsy rates over time in
our population. The increasing use of sophisticated
diagnostic imaging raises the possibility of detection
bias for smaller SAH. Finally, we were unable to
determine SAH etiology with certainty in a substantial
portion across time periods, especially in 1988.
In our population, SAH incidence remained
unchanged across several time points but case-
fatality declined. Future studies should explore poten-
tial differential effects of sex and race on SAH
incidence and outcomes. Future studies should also
explore how specific factors and processes of care lead
to improved outcomes and the effect of these inter-
ventions on patient-centered outcomes such as qual-
ity of life and neuropsychological outcomes.
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Save These Dates for AAN CME Opportunities!
Mark these dates on your calendar for exciting continuing education conferences by the American
Academy of Neurology. Learn more at AAN.com/conferences.
Breakthroughs in Neurology
• January 13–16, 2017, Phoenix, AZ, at the Sheraton Grand at Wild Horse Pass
AAN Annual Meeting
• April 22–28, 2017, Boston, MA, at the Boston Convention Center
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